Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3993460 | 0.81 | CNR2 (0.42) | CNR2 | |
| SCHEMBL3990759 | 0.79 | ALDH1A1 (0.42) | JMJD6 | |
| Hydrochloric Acid SCHEMBL3996591 | 0.74 | HTR4 (0.35) | JMJD6PDE1CACHEHTR4CHRNB2 | |
| SCHEMBL2370225 | 0.70 | PARP1 (0.40) | — | |
| SCHEMBL2369513 | 0.69 | PARP1 (0.36) | — | |
| SCHEMBL4882771 | 0.61 | PARP15 (0.41) | JMJD6PDE1CPARP15PARP10PARP2 | |
| SCHEMBL5592954 | 0.61 | JMJD6 (0.44) | JMJD6PDE1CPARP15PARP10 | |
| SCHEMBL3988800 | 0.61 | KMT2A (0.44) | — | |
| SCHEMBL9002096 | 0.61 | CHRNB4 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4CNR2 | |
| SCHEMBL30409769 | 0.59 | CHRNB2 (0.51) | CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589206-B2 | Pyrrolopyridine derivatives | GLAXO GROUP LIMITED (GB) | 2009-09-15 | — | — | US | disclosed |
| EP-1753764-B1 | PYRROLOPYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2008-10-29 | — | — | EP | disclosed |
| US-20070219229-A1 | Pyrrolopyridine Derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-20 | — | — | US | disclosed |
| EP-1753764-A1 | PYRROLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005121140-A1 | PYRROLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219229-A1 | Pyrrolopyridine Derivatives | CNR2, CNR1, TRPV1 | JMJD6 2427/4885PDE1C 1339/4885PARP15 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.